Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor nai indicated for treatment of acute uncomplicated influenza a and b in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours 1 1 prophylaxis of influenza a and b in patients 1 year and older 1 2 limitations of use not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1 3 not recommended for patients with end stage renal disease not undergoing dialysis 1 3 oseltamivir phosphate for oral suspension is indicated for the treatment of acute uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza a and b in patients 1 year and older oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral suspension see microbiology 12 4 oseltamivir phosphate for oral suspension is not recommended for patients with end stage renal disease not undergoing dialysis see dosage and administration 2 4 use in specific populations 8 6" ?g. }

• association label "oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor nai indicated for treatment of acute uncomplicated influenza a and b in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours 1 1 prophylaxis of influenza a and b in patients 1 year and older 1 2 limitations of use not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1 3 not recommended for patients with end stage renal disease not undergoing dialysis 1 3 oseltamivir phosphate for oral suspension is indicated for the treatment of acute uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza a and b in patients 1 year and older oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral suspension see microbiology 12 4 oseltamivir phosphate for oral suspension is not recommended for patients with end stage renal disease not undergoing dialysis see dosage and administration 2 4 use in specific populations 8 6" assertion.